These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33581493)

  • 1. Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients.
    Barakat M; Albitar M; Whitney R; Abdulhaq H
    Cancer Treat Res Commun; 2021; 27():100310. PubMed ID: 33581493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.
    Zhou Y; Liu W; Xu Z; Zhu H; Xiao D; Su W; Zeng R; Feng Y; Duan Y; Zhou J; Zhong M
    Neoplasia; 2018 Oct; 20(10):1059-1069. PubMed ID: 30227305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of genomic alterations in primary central nervous system lymphomas.
    Zorofchian S; El-Achi H; Yan Y; Esquenazi Y; Ballester LY
    J Neurooncol; 2018 Dec; 140(3):509-517. PubMed ID: 30171453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.
    Braggio E; Van Wier S; Ojha J; McPhail E; Asmann YW; Egan J; da Silva JA; Schiff D; Lopes MB; Decker PA; Valdez R; Tibes R; Eckloff B; Witzig TE; Stewart AK; Fonseca R; O'Neill BP
    Clin Cancer Res; 2015 Sep; 21(17):3986-94. PubMed ID: 25991819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.
    Xie Z; Qin Y; Chen X; Yang S; Yang J; Gui L; Liu P; He X; Zhou S; Zhang C; Tang L; Shi Y
    Target Oncol; 2024 May; 19(3):383-400. PubMed ID: 38643457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
    Montesinos-Rongen M; Brunn A; Tuchscherer A; Borchmann P; Schorb E; Kasenda B; Altmüller J; Illerhaus G; Ruge MI; Maarouf M; Büttner R; Hansmann ML; Hallek M; Prinz M; Siebert R; Deckert M
    J Mol Diagn; 2020 Oct; 22(10):1300-1307. PubMed ID: 32745612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
    Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R
    Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Study on the Clinicopathologic and Molecular Characteristics of Primary and Secondary Diffuse Large B-cell Lymphoma in the Central Nervous System.
    DO J; Yenwongfai LN; DO SI; Kim SW; Na K
    Anticancer Res; 2024 Jul; 44(7):2953-2960. PubMed ID: 38925823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma.
    Bödör C; Alpár D; Marosvári D; Galik B; Rajnai H; Bátai B; Nagy Á; Kajtár B; Burján A; Deák B; Schneider T; Alizadeh H; Matolcsy A; Brandner S; Storhoff J; Chen N; Liu M; Ghali N; Csala I; Bagó AG; Gyenesei A; Reiniger L
    J Neuropathol Exp Neurol; 2020 Feb; 79(2):176-183. PubMed ID: 31886867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.
    Nakamura T; Tateishi K; Niwa T; Matsushita Y; Tamura K; Kinoshita M; Tanaka K; Fukushima S; Takami H; Arita H; Kubo A; Shuto T; Ohno M; Miyakita Y; Kocialkowski S; Sasayama T; Hashimoto N; Maehara T; Shibui S; Ushijima T; Kawahara N; Narita Y; Ichimura K
    Neuropathol Appl Neurobiol; 2016 Apr; 42(3):279-90. PubMed ID: 26111727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
    Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
    Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
    Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
    Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
    Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
    Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of surgical resection in primary central nervous system lymphoma: a single-center retrospective analysis of 70 patients.
    Wu S; Wang J; Liu W; Hu F; Zhao K; Jiang W; Lei T; Shu K
    BMC Neurol; 2021 May; 21(1):190. PubMed ID: 33975554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.
    Hiemcke-Jiwa LS; Leguit RJ; Snijders TJ; Jiwa NM; Kuiper JJW; de Weger RA; Minnema MC; Huibers MMH
    Crit Rev Oncol Hematol; 2018 Jul; 127():56-65. PubMed ID: 29891112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
    Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
    Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, Treatment and Prognosis of Primary Central Nervous System Lymphoma.
    Jin Q; Jiang H; Han Y; Li C; Zhang L; Zhang Y; Chai Y; Zeng P; Yue L; Wu C
    World Neurosurg; 2023 Feb; 170():99-106. PubMed ID: 36396049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of genomic alterations in primary central nervous system lymphoma.
    He X; Fan X; Shan Y; Ji X; Su L; Wang Y
    Medicine (Baltimore); 2023 Sep; 102(35):e34931. PubMed ID: 37657032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
    Cao XX; Li J; Cai H; Zhang W; Duan MH; Zhou DB
    Ann Hematol; 2017 Nov; 96(11):1867-1871. PubMed ID: 28803429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational analysis of primary central nervous system lymphoma.
    Bruno A; Boisselier B; Labreche K; Marie Y; Polivka M; Jouvet A; Adam C; Figarella-Branger D; Miquel C; Eimer S; Houillier C; Soussain C; Mokhtari K; Daveau R; Hoang-Xuan K
    Oncotarget; 2014 Jul; 5(13):5065-75. PubMed ID: 24970810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.